Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 13/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1827051 | 0.90 | MRGPRX4 (0.60) | MRGPRX4KDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL1825782 | 0.89 | MRGPRX4 (0.56) | MRGPRX4KDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL1822283 | 0.89 | MRGPRX4 (0.56) | MRGPRX4KDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL1826233 | 0.89 | MRGPRX4 (0.57) | MRGPRX4KDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL1824562 | 0.89 | MRGPRX4 (0.60) | MRGPRX4KDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL1827353 | 0.86 | MRGPRX4 (0.58) | MRGPRX4KDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL1824100 | 0.86 | MRGPRX4 (0.71) | MRGPRX4 | |
| SCHEMBL1825540 | 0.84 | MRGPRX4 (0.65) | MRGPRX4KDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL1825080 | 0.84 | MRGPRX4 (0.56) | MRGPRX4KDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL22480822 | 0.81 | MRGPRX4 (1.00) | MRGPRX4ALDH1A1NPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461205-B2 | Anthranilic acid derivatives | CHELSEA THERAPEUTICS, INC. (US) | 2013-06-11 | — | — | US | claimed |
| US-20120283326-A1 | ANTHRANILIC ACID DERIVATIVES | CHELSEA THERAPEUTICS, INC. | 2012-11-08 | — | — | US | claimed |
| US-8263658-B2 | Anthranilic acid derivatives | CHELSEA THERAPEUTICS, INC. (US) | 2012-09-11 | — | — | US | claimed |
| EP-2118051-B1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | CHELSEA THERAPEUTICS INC (US) | 2011-05-04 | — | — | EP | claimed |
| US-20100029767-A1 | ANTHRANILIC ACID DERIVATIVES | Chelsea Therapeutics, Inc | 2010-02-04 | — | — | US | claimed |
| EP-2118051-A1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | Chelsea Therapeutics, Inc. (US) | 2009-11-18 | — | — | EP | claimed |
| WO-2008097180-A1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | CHELSEA THERAPEUTICS, INC. (US) | 2008-08-14 | — | — | WO | claimed |
| US-8461205-B2 | Anthranilic acid derivatives | CHELSEA THERAPEUTICS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120283326-A1 | ANTHRANILIC ACID DERIVATIVES | CHELSEA THERAPEUTICS, INC. | 2012-11-08 | — | — | US | disclosed |
| US-8263658-B2 | Anthranilic acid derivatives | CHELSEA THERAPEUTICS, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| EP-2118051-B1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | CHELSEA THERAPEUTICS INC (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20100029767-A1 | ANTHRANILIC ACID DERIVATIVES | Chelsea Therapeutics, Inc | 2010-02-04 | — | — | US | disclosed |
| EP-2118051-A1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | Chelsea Therapeutics, Inc. (US) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008097180-A1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | CHELSEA THERAPEUTICS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283326-A1 | ANTHRANILIC ACID DERIVATIVES | ACOX3, BCL3, AOC3 | MRGPRX4 1127/4885KDM4E 4207/4885MAPT 4784/4885 |
| US-20100029767-A1 | ANTHRANILIC ACID DERIVATIVES | ACOX3, BCL3, AOC3 | MRGPRX4 1135/4885KDM4E 4172/4885MAPT 4786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.